{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T19:39:38Z","timestamp":1792525178542,"version":"4.5.0"},"reference-count":40,"publisher":"American Diabetes Association","issue":"11","license":[{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.diabetesjournals.org\/journals\/pages\/license"}],"funder":[{"name":"National Institutes of Health (NIH","award":["K01AG068365"],"award-info":[{"award-number":["K01AG068365"]}]},{"DOI":"10.13039\/100000041","name":"American Diabetes Association","doi-asserted-by":"publisher","award":["1-25-PDF-66"],"award-info":[{"award-number":["1-25-PDF-66"]}],"id":[{"id":"10.13039\/100000041","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000041","name":"American Diabetes Association","doi-asserted-by":"publisher","award":["7-21-JDFM-005"],"award-info":[{"award-number":["7-21-JDFM-005"]}],"id":[{"id":"10.13039\/100000041","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,11,1]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>To compare the risk of motility-related gastrointestinal (GI) events associated with commonly prescribed opioids among adults with type 2 diabetes (T2D) prescribed glucagon-like peptide 1 receptor agonist (GLP-1RA) therapy, a population in whom the GI safety of concomitant opioid use has not been well characterized.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESEARCH DESIGN AND METHODS<\/jats:title>\n                    <jats:p>A population-based, new-user cohort study was conducted using U.S. insurance claims (2016\u20132025) among adults with T2D prescribed GLP-1RA therapy who initiated use of oxycodone, hydrocodone, or tramadol. We evaluated a composite of motility-related GI events, including severe constipation, bowel obstruction, and gastroparesis, and estimated 30-day weighted absolute risks, risk ratios (RRs), and risk differences (RDs) using propensity score\u2013matching weights.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>Among 411,188 patients (mean age 62.8 years; 53.8% female) with T2D and using a GLP-1RA, 24.4% initiated use of oxycodone, 48.5% hydrocodone, and 27.1% tramadol. The weighted 30-day absolute risk of motility-related GI events was 0.51% for oxycodone, 0.35% for hydrocodone, and 0.33% for tramadol. Oxycodone was associated with a higher risk than hydrocodone (RR 1.48 [95% CI 1.30\u20131.69]; RD 0.17 [95% CI 0.11\u20130.22]) and tramadol (RR 1.55 [95% CI 1.33\u20131.79]; RD 0.18 [95% CI 0.12\u20130.24]). Hydrocodone and tramadol showed similar risks (RR 1.05 [95% CI 0.91\u20131.21]; RD 0.02 [95% CI \u22120.03 to 0.06]).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>Among adults with T2D who were using a GLP-1RA, initiation of oxycodone was associated with higher short-term risks of severe constipation and bowel obstruction compared with hydrocodone or tramadol. We did not observe differences in the risk of gastroparesis. Risks were similar between patients initiating hydrocodone and tramadol, although variation across secondary analyses warrants cautious interpretation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2337\/dc26-0757","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T14:49:00Z","timestamp":1788360540000},"page":"2050-2059","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":0,"title":["Comparative Short-term Risk of Severe Gastrointestinal Events Associated With Opioid Type Among Patients Receiving Glucagon-Like Peptide 1 Receptor Agonists"],"prefix":"10.2337","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2622-6553","authenticated-orcid":false,"given":"Sungho","family":"Bea","sequence":"first","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School 1 , Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Patorno","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School 1 , Boston, MA"},{"name":"Division of General Internal Medicine & Health Services Research, Department of Medicine, David Geffen School of Medicine at UCLA 2 , Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushama Kattinakere","family":"Sreedhara","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School 1 , Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah J.","family":"Wexler","sequence":"additional","affiliation":[{"name":"Diabetes Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School 3 , Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara J.","family":"Cromer","sequence":"additional","affiliation":[{"name":"Diabetes Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School 3 , Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Glynn","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School 1 , Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie M.","family":"Paik","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School 1 , Boston, MA"},{"name":"Division of Renal (Kidney) Medicine, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School 4 , Boston, MA"},{"name":"New England Geriatric Research Education and Clinical Center, VA Boston Healthcare System 5 , Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3336-5412","authenticated-orcid":false,"given":"Katsiaryna","family":"Bykov","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School 1 , Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2026,9,2]]},"reference":[{"key":"2026102014530950300_B1","doi-asserted-by":"crossref","first-page":"110240","DOI":"10.1016\/j.diabres.2023.110240","article-title":"Opioid prescription and diabetes among Medicare beneficiaries","volume":"196","author":"Casagrande","year":"2023","journal-title":"Diabetes Res Clin Pract"},{"key":"2026102014530950300_B2","doi-asserted-by":"crossref","first-page":"e2035632","DOI":"10.1001\/jamanetworkopen.2020.35632","article-title":"Trends in pain medication initiation among patients with newly diagnosed diabetic peripheral neuropathy, 2014-2018","volume":"4","author":"Fan","year":"2021","journal-title":"JAMA Netw Open"},{"key":"2026102014530950300_B3","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1007\/s00198-020-05519-5","article-title":"Risk of fragility fractures in obesity and diabetes: a retrospective analysis on a nation-wide cohort","volume":"31","author":"Adami","year":"2020","journal-title":"Osteoporos Int"},{"key":"2026102014530950300_B4","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S2213-8587(21)00347-8","article-title":"Bone fragility in diabetes: novel concepts and clinical implications","volume":"10","author":"Hofbauer","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026102014530950300_B5","doi-asserted-by":"crossref","first-page":"8142","DOI":"10.1038\/s41598-021-87615-y","article-title":"Diabetes is associated with greater leg pain and worse patient-reported outcomes at 1 year after lumbar spine surgery","volume":"11","author":"Nagata","year":"2021","journal-title":"Sci Rep"},{"key":"2026102014530950300_B6","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.jss.2024.07.124","article-title":"Association between diabetes mellitus and postoperative opioid use: a meta-analysis","volume":"302","author":"Wu","year":"2024","journal-title":"J Surg Res"},{"key":"2026102014530950300_B7","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.2337\/dc20-0204","article-title":"Association of type 2 diabetes with cancer: a meta-analysis with bias analysis for unmeasured confounding in 151 cohorts comprising 32 million people","volume":"43","author":"Ling","year":"2020","journal-title":"Diabetes Care"},{"key":"2026102014530950300_B8","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1016\/j.cgh.2017.05.014","article-title":"Opioids in gastroenterology: treating adverse effects and creating therapeutic benefits","volume":"15","author":"Camilleri","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026102014530950300_B9","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.regpep.2009.03.012","article-title":"Opioid receptors in the gastrointestinal tract","volume":"155","author":"Holzer","year":"2009","journal-title":"Regul Pept"},{"key":"2026102014530950300_B10","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.2147\/JPR.S138698","article-title":"Opioid analgesics-related pharmacokinetic drug interactions: from the perspectives of evidence based on randomized controlled trials and clinical risk management","volume":"10","author":"Feng","year":"2017","journal-title":"J Pain Res"},{"key":"2026102014530950300_B11","doi-asserted-by":"crossref","first-page":"6079","DOI":"10.2174\/138161212803582423","article-title":"Non-analgesic effects of opioids: interactions between opioids and other drugs","volume":"18","author":"Heiskanen","year":"2012","journal-title":"Curr Pharm Des"},{"key":"2026102014530950300_B12","first-page":"S276","article-title":"Opioid pharmacokinetic drug-drug interactions","volume":"17","author":"Overholser","year":"2011","journal-title":"Am J Manag Care"},{"key":"2026102014530950300_B13","doi-asserted-by":"crossref","first-page":"S181","DOI":"10.2337\/dc25-S009","article-title":"9. Pharmacologic approaches to glycemic treatment: Standards of Care in Diabetes\u20132025","volume":"48","author":"American Diabetes Association Professional Practice Committee","year":"2025","journal-title":"Diabetes Care"},{"key":"2026102014530950300_B14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/ANNALS-25-01724","article-title":"Comparative gastrointestinal safety of dulaglutide, semaglutide, and tirzepatide in adults with type 2 diabetes","volume":"179","author":"Crisafulli","year":"2026","journal-title":"Ann Intern Med"},{"key":"2026102014530950300_B15","doi-asserted-by":"crossref","first-page":"280","DOI":"10.2337\/dc23-1791","article-title":"Occurrence of gastrointestinal adverse events upon GLP-1 receptor agonist initiation with concomitant metformin use: a post hoc analysis of LEADER, STEP 2, SUSTAIN-6, and PIONEER 6","volume":"47","author":"Klein","year":"2024","journal-title":"Diabetes Care"},{"key":"2026102014530950300_B16","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1001\/jama.2023.19574","article-title":"Risk of gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists for weight loss","volume":"330","author":"Sodhi","year":"2023","journal-title":"JAMA"},{"key":"2026102014530950300_B17","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S2468-1253(24)00188-2","article-title":"Gastrointestinal effects of GLP-1 receptor agonists: mechanisms, management, and future directions","volume":"9","author":"Jalleh","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026102014530950300_B18","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2147\/DMSO.S141235","article-title":"Reasons for discontinuation of GLP1 receptor agonists: data from a real-world cross-sectional survey of physicians and their patients with type 2 diabetes","volume":"10","author":"Sikirica","year":"2017","journal-title":"Diabetes Metab Syndr Obes"},{"key":"2026102014530950300_B19","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/j.1365-2125.2012.04317.x","article-title":"Differences between opioids: pharmacological, experimental, clinical and economical perspectives","volume":"75","author":"Drewes","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"2026102014530950300_B20","doi-asserted-by":"crossref","first-page":"S133","DOI":"10.36076\/ppj.2008\/11\/S133","article-title":"Opioid pharmacology","volume":"11","author":"Trescot","year":"2008","journal-title":"Pain Physician"},{"key":"2026102014530950300_B21","unstructured":"U.S. Food and Drug Administration (FDA)\n          . FDA analysis of long-term trends in prescription opioid analgesic products: quantity, sales, and price trends. 2018. FDA. Accessed 28 March 2026. Available from https:\/\/www.fda.gov\/media\/111695\/download"},{"key":"2026102014530950300_B22","first-page":"1","article-title":"Trends in opioids prescribed at discharge from emergency departments among adults: United States, 2006-2017","author":"Rui","year":"2020","journal-title":"Natl Health Stat Report"},{"key":"2026102014530950300_B23","unstructured":"Bloschichak\n              A\n            , HargravesJ. Opioid prescriptions declined 32% for the commercially insured over 10 years (2008\u20132017). Health Care Cost Institute; 2019. Accessed 3 April 2026. Available from https:\/\/healthcostinstitute.org\/all-hcci-reports\/opioid-10yr-trends\/."},{"key":"2026102014530950300_B24","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1001\/jamainternmed.2020.0989","article-title":"Trends in utilization of prescribed controlled substances in US commercially insured adults, 2004-2019","volume":"180","author":"Bykov","year":"2020","journal-title":"JAMA Intern Med"},{"key":"2026102014530950300_B25","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.amepre.2024.06.009","article-title":"Tramadol use in U.S. adults with commercial health insurance, 2005-2021","volume":"67","author":"Basham","year":"2024","journal-title":"Am J Prev Med"},{"key":"2026102014530950300_B26","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s40471-015-0053-5","article-title":"The active comparator, new user study design in pharmacoepidemiology: historical foundations and contemporary application","volume":"2","author":"Lund","year":"2015","journal-title":"Curr Epidemiol Rep"},{"key":"2026102014530950300_B27","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1093\/aje\/kwae087","article-title":"Building transparency and reproducibility into the practice of pharmacoepidemiology and outcomes research","volume":"193","author":"Wang","year":"2024","journal-title":"Am J Epidemiol"},{"key":"2026102014530950300_B28","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1001\/jama.2016.1464","article-title":"CDC guideline for prescribing opioids for chronic pain\u2013United States, 2016","volume":"315","author":"Dowell","year":"2016","journal-title":"JAMA"},{"key":"2026102014530950300_B29","doi-asserted-by":"crossref","first-page":"7494","DOI":"10.1111\/dom.70963","article-title":"Glucagon-like peptide-1 based therapies and the risk of severe gastrointestinal motility adverse events: a cohort study","volume":"28","author":"Alkabbani","year":"2026","journal-title":"Diabetes Obes Metab"},{"key":"2026102014530950300_B30","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1093\/aje\/kwj149","article-title":"Variable selection for propensity score models","volume":"163","author":"Brookhart","year":"2006","journal-title":"Am J Epidemiol"},{"key":"2026102014530950300_B31","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1111\/dom.14512","article-title":"Validation of obesity-related diagnosis codes in claims data","volume":"23","author":"Suissa","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"2026102014530950300_B32","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1093\/gerona\/glx229","article-title":"Measuring frailty in Medicare Data: development and Validation of a claims-based frailty index","volume":"73","author":"Kim","year":"2018","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"2026102014530950300_B33","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1515\/ijb-2012-0030","article-title":"A weighting analogue to pair matching in propensity score analysis","volume":"9","author":"Li","year":"2013","journal-title":"Int J Biostat"},{"key":"2026102014530950300_B34","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1093\/aje\/kwaa044","article-title":"Estimating risk ratios and risk differences using regression","volume":"189","author":"Naimi","year":"2020","journal-title":"Am J Epidemiol"},{"key":"2026102014530950300_B35","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1093\/ije\/dyv137","article-title":"Standardized binomial models for risk or prevalence ratios and differences","volume":"44","author":"Richardson","year":"2015","journal-title":"Int J Epidemiol"},{"key":"2026102014530950300_B36","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1186\/s12916-025-04118-7","article-title":"Comparative risk of severe constipation in patients treated with opioids for non-cancer pain: a retrospective cohort study in northwest England","volume":"23","author":"Yimer","year":"2025","journal-title":"BMC Med"},{"key":"2026102014530950300_B37","doi-asserted-by":"crossref","first-page":"e119156","DOI":"10.5812\/aapm.119156","article-title":"Full opioid agonists and tramadol: pharmacological and clinical considerations","volume":"11","author":"Edinoff","year":"2021","journal-title":"Anesth Pain Med"},{"key":"2026102014530950300_B38","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1053\/j.gastro.2025.06.003","article-title":"Glucagon-like peptide-1 receptor agonists and gastrointestinal adverse events: a systematic review and meta-analysis","volume":"169","author":"Chiang","year":"2025","journal-title":"Gastroenterology"},{"key":"2026102014530950300_B39","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1111\/j.1572-0241.2001.03536.x","article-title":"Narcotic analgesic effects on the sphincter of Oddi: a review of the data and therapeutic implications in treating pancreatitis","volume":"96","author":"Thompson","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"2026102014530950300_B40","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1093\/aje\/kwac035","article-title":"Misconceptions about the direction of bias from nondifferential misclassification","volume":"191","author":"Yland","year":"2022","journal-title":"Am J Epidemiol"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/49\/11\/2050\/893790\/dc260757.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/49\/11\/2050\/893790\/dc260757.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T18:53:16Z","timestamp":1792522396000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/49\/11\/2050\/172430\/Comparative-Short-term-Risk-of-Severe"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,2]]},"references-count":40,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,9,2]]},"published-print":{"date-parts":[[2026,11,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc26-0757","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,2]]}}}